StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3060% above fair value
$69.31+0.34 (+0.49%)

Close on Nov 13, 2026Market cap $39.85BP/E 48.8Yield –

Royalty Pharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Royalty Pharma's profit margin for the twelve months ending Sep 30, 2026 was 25.7%. For fiscal 2025 it was 32.4%, against 37.9% the year before. The highest annual figure on record is 129.4% in fiscal 2019.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202532.4%−5.5
FY2024Dec 31, 202437.9%−10.2
FY2023Dec 31, 202348.2%+46.3
FY2022Dec 31, 20221.9%−25.2
FY2021Dec 31, 202127.1%−18.9
FY2020Dec 31, 202045.9%−83.5
FY2019Dec 31, 2019129.4%+52.7
FY2018Dec 31, 201876.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202621.0%−25.7
Q2 FY2026Jun 30, 20262.7%−2.9
Q1 FY2026Mar 31, 202646.7%+4.6
Q4 FY2025Dec 31, 202534.6%−0.5
Q3 FY2025Sep 30, 202546.6%−49.7
Q2 FY2025Jun 30, 20255.6%−13.4
Q1 FY2025Mar 31, 202542.1%+41.3
Q4 FY2024Dec 31, 202435.1%−47.9
Q3 FY2024Sep 30, 202496.3%+82.9
Q2 FY2024Jun 30, 202419.0%−23.3
Q1 FY2024Mar 31, 20240.8%−49.0
Q4 FY2023Dec 31, 202382.9%+163.5
Q3 FY2023Sep 30, 202313.4%−11.4
Q2 FY2023Jun 30, 202342.3%−14.5
Q1 FY2023Mar 31, 202349.8%+40.6
Q4 FY2022Dec 31, 2022-80.6%−82.0
Q3 FY2022Sep 30, 202224.9%+7.5
Q2 FY2022Jun 30, 202256.8%−22.6
Q1 FY2022Mar 31, 20229.2%−2.9
Q4 FY2021Dec 31, 20211.4%−28.5
Q3 FY2021Sep 30, 202117.4%−36.6
Q2 FY2021Jun 30, 202179.4%−7.1
Q1 FY2021Mar 31, 202112.1%−2.2
Q4 FY2020Dec 31, 202029.9%−280.6
Q3 FY2020Sep 30, 202054.0%−34.1
Q2 FY2020Jun 30, 202086.5%+53.4
Q1 FY2020Mar 31, 202014.2%–
Q4 FY2019Dec 31, 2019310.5%–
Q3 FY2019Sep 30, 201988.1%–
Q2 FY2019Jun 30, 201933.2%–

More Royalty Pharma figures

See a number that looks wrong?